Zhejiang Jingxin Pharmaceutical Co., Ltd.

浙江京新药业股份有限公司

Pharmaceutical group in China developing and selling drugs focused on CNS disorders and cardiovascular/cerebrovascular diseases, including generics, the innovative drug Dimdazenil, TCM, biologics, APIs, and medical equipment. 2025 revenue was RMB4,069.4 million with net profit of RMB771.7 million.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Leased property
• Owned property & construction permits
• Social insurance & housing fund
• Third-party payments, personal accounts & cash
• Tax, invoices & subsidies
• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Connected or related major customers / suppliers
• Distribution model
• Reliance on platforms, partners or licences
• Raw material and commodity prices
• Pricing policy and price changes
• Overseas markets and operations
• Capacity and utilisation
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Investments and fair-value assets
• Related-party transactions and balances
• Sanctioned countries and export controls